Survodutide Shows Promise for Obesity and Liver Disease in Phase III Trials

Phase III trial results for survodutide, a new dual agonist, demonstrate significant weight loss and reductions in visceral and liver fat. Participants experienced substantial body weight reduction without muscle mass compromise, and many with MASLD achieved liver fat normalization. These findings suggest survodutide could be a disease-modifying treatment for both obesity and MASLD.